<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>First-line treatment of metastatic castration-resistant prostate cancer associated with a &lt;em&gt;BRCA&lt;/em&gt; mutation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">First-line treatment of metastatic castration-resistant prostate cancer associated with a <em>BRCA</em> mutation</h1>
<div class="graphic"><div class="figure"><div class="ttl">First-line treatment of metastatic castration-resistant prostate cancer associated with a <em>BRCA</em> mutation</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd"><p>Males with advanced prostate cancer who have evidence of disease progression (eg, an increase in serum prostate-specific antigen [PSA], new metastases, or progression of existing metastases) and who have castrate levels of serum testosterone (&lt;50 ng/dL) are considered to have castration-resistant prostate cancer (CRPC).</p>
Systemic treatment for metastatic castration-sensitive prostate cancer is not influenced by the presence of a deleterious <em>BRCA</em> mutation and is reviewed in other UpToDate content.</div><div class="graphic_footnotes">ADT: androgen deprivation therapy; <em>BRCA</em>: breast cancer susceptibility gene.</div><div id="graphicVersion">Graphic 143093 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
